[Chemotherapy with low-dose docetaxel and estramustine phosphate in patient with liver dysfunction due to liver metastases of hormone-refractory prostate cancer : a case report]

Hinyokika Kiyo. 2010 Jan;56(1):45-8.
[Article in Japanese]

Abstract

A 82-year-old man was referred to our hospital for treatment of hormone-refractory prostate cancer with liver metastases. The obstruction of intrahepatic bile ducts due to the rapid growth of liver metastases induced liver dysfunction. We administered 25 mg/m(2) docetaxel on day1 and 280 mg/body estramustine phosphate on day 1 to day 3, every 4 weeks. After two courses of this combined chemothrapy, the liver metastases were markedly reduced in size with the rapid improvement of liver function.

Publication types

  • Case Reports

MeSH terms

  • Aged, 80 and over
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents, Alkylating / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Docetaxel
  • Estramustine / administration & dosage
  • Humans
  • Liver Diseases / drug therapy
  • Liver Diseases / etiology
  • Liver Neoplasms / complications
  • Liver Neoplasms / drug therapy*
  • Liver Neoplasms / secondary*
  • Male
  • Prostatic Neoplasms / drug therapy*
  • Prostatic Neoplasms / pathology
  • Taxoids / administration & dosage

Substances

  • Antineoplastic Agents
  • Antineoplastic Agents, Alkylating
  • Taxoids
  • Docetaxel
  • Estramustine